- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 9, Issue 12, 2003
Current Pharmaceutical Design - Volume 9, Issue 12, 2003
Volume 9, Issue 12, 2003
-
-
Immune Therapy for Infectious Diseases at the Dawn of the 21st Century: the Past, Present and Future Role of Antibody Therapy, Therapeutic Vaccination and Biological Response Modifiers
Authors: U.K. Buchwald and L. PirofskiIn the last decades of the 20th century, infectious diseases have re-emerged as a significant public health problem in the developed world. However, the available anti-infective armamentarium has proven to be alarmingly insufficient to combat many of the microbes that cause these diseases, such as drug resistant microbes, microbes for which therapy is not available or ineffective because of underlying host immune Read More
-
-
-
The Application of Information Technology to Regional, National, and Global Surveillance of Antimicrobial Resistance
Authors: D.F. Sahm, C. Thornsberry and J.A. KarlowskyEstablishing local, national, and global surveillance networks for monitoring the dissemination of antimicrobial resistance and detecting the emergence of new resistance mechanisms has been recommended by the American Society for Microbiology Task Force on Antibiotic Resistance and other national organizations. While the need to develop and deploy surveillance strategies cannot be argued, the design and imple Read More
-
-
-
Infections and Urinary Stone Disease
Authors: N.U. Rahman, M.V. Meng and M.L. StollerThe relationship between urinary infections and stone formation has been recognized since antiquity and it has been over a century since bacterial degradation of urea was postulated to cause struvite stones. Specific therapy for urease-producing bacteria, such as urease-inhibitors and antibiotics, has allowed for treatment for this subset of urinary stones. Future directions for research include development of novel urea Read More
-
-
-
Separating Fact from Fiction: The Data Behind Allergies and Side Effects Caused by Penicillins, Cephalosporins, and Carbapenem Antibiotics
By I. LevitonAntibiotics developed over the past quarter century have greatly improved toxic to therapeutic ratios compared to older agents. This is due to both a wider spectrum of in vitro antibacterial activity and less frequent side effects. In combination with once daily dosing and nearly complete bioavailability of some newer agents, the better risk to benefit ratios have led to empiric antibiotic use in many situations even when bac Read More
-
-
-
Antibiotic Prophylaxis in Urologic Prosthetic Surgery
Authors: A. Gomelsky and R.R. DmochowskiThe implantation of prosthetic devices is an ever-increasing practice in urologic surgery. The most common devices are penile prostheses, artificial urinary sphincters, synthetic pubovaginal slings, and bone anchors used for pelvic floor reconstruction and incontinence surgery. While their efficacy has been supported over time, infection and rejection are severe complications. Explantation of the entire prosthetic device has Read More
-
-
-
The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Authors: D. Ganea and M. DelgadoThe structurally related neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) are released within the lymphoid organs following antigenic stimulation, and modulate the function of inflammatory cells through specific receptors. In activated macrophages, VIP and PACAP inhibit the expression at both mRNA and protein level of pro-inflammatory cytokines and chemo Read More
-
-
-
Interactions of VIP, Secretin and PACAP1-38 with Phospholipids: A Biological Paradox Revisited
Authors: A. Krishnadas, H. Onyuksel and I. RubinsteinVasoactive intestinal peptide (VIP), secretin and pituitary adenylate cyclase-activating peptide1-38 (PACAP1-38) are widely distributed amphipathic mammalian neuropeptides that exert diverse biological effects in target tissues located distant from their site of release. However, the half-life of exogenously-administered VIP, secretin and PACAP1-38 in the bloodstream is relatively short (minutes) due to rapid degradation and ina Read More
-
-
-
Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
By B.C. YegenBombesin (BBS) is proved to have a wide variety of the pharmacologic effects, including effects on the release of gastrointestinal hormones and control of gastrointestinal motility. More recently, the role of BBS in tumor growth, cellular proliferation and inflammation has attracted attention. There is evidence that increased BBS receptor expression may be considered as a specific marker for small-cell lung cancer, colorectal Read More
-
-
-
Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology
Authors: G.N. Chaldakov, I.S. Stankulov, M. Hristova and P.I. GhenevIn recent years, the simple paradigm of adipose tissue as merely a fat store is rapidly evolving into a complex paradigm of this tissue as multipotential secretory organ, partitioned into a few large depots, including visceral and subcutaneous location, and many small depots, associated with a variety of organs in the human body. The major secretory compartment of adipose tissue consists of adipocytes, fibro Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
